Swiss National Bank Acquires Shares of 22,100 Septerna, Inc. $SEPN

Swiss National Bank acquired a new stake in Septerna, Inc. (NASDAQ:SEPN) in the first quarter, HoldingsChannel.com reports. The fund acquired 22,100 shares of the company’s stock, valued at approximately $531,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Group One Trading LLC lifted its holdings in Septerna by 111.8% during the 4th quarter. Group One Trading LLC now owns 944 shares of the company’s stock valued at $26,000 after purchasing an additional 8,955 shares during the last quarter. Global Retirement Partners LLC acquired a new position in shares of Septerna in the fourth quarter valued at $35,000. Russell Investments Group Ltd. bought a new position in shares of Septerna in the third quarter valued at about $36,000. Caitong International Asset Management Co. Ltd bought a new position in shares of Septerna in the fourth quarter valued at about $53,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Septerna during the 4th quarter worth about $61,000.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on SEPN. Guggenheim reduced their target price on shares of Septerna from $52.00 to $45.00 and set a “buy” rating for the company in a report on Wednesday, July 1st. HC Wainwright reissued a “buy” rating and issued a $40.00 price target on shares of Septerna in a report on Wednesday, July 1st. Raymond James Financial raised their price objective on shares of Septerna from $47.00 to $53.00 and gave the stock a “strong-buy” rating in a research report on Monday, June 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Septerna in a report on Friday, July 17th. Finally, Stifel Nicolaus began coverage on Septerna in a research report on Friday, May 1st. They issued a “buy” rating and a $43.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Septerna presently has an average rating of “Moderate Buy” and an average price target of $45.89.

Insiders Place Their Bets

In other news, insider Samira Shaikhly sold 11,798 shares of the company’s stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $30.06, for a total transaction of $354,647.88. Following the completion of the sale, the insider directly owned 793 shares in the company, valued at approximately $23,837.58. This represents a 93.70% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, SVP Daniel D. Long sold 15,000 shares of the stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $35.51, for a total value of $532,650.00. Following the sale, the senior vice president directly owned 96,412 shares in the company, valued at approximately $3,423,590.12. This trade represents a 13.46% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 44,494 shares of company stock worth $1,469,391. Corporate insiders own 5.80% of the company’s stock.

Septerna Stock Down 2.1%

Shares of NASDAQ:SEPN opened at $34.45 on Friday. Septerna, Inc. has a 12-month low of $10.62 and a 12-month high of $38.04. The company’s 50 day moving average price is $33.58 and its two-hundred day moving average price is $28.58. The firm has a market cap of $1.55 billion, a PE ratio of -42.53 and a beta of 2.29.

Septerna (NASDAQ:SEPN) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.19) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.23. The company had revenue of $26.52 million during the quarter, compared to the consensus estimate of $16.98 million. Septerna had a negative net margin of 49.88% and a negative return on equity of 12.72%. On average, research analysts expect that Septerna, Inc. will post -1.59 EPS for the current year.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.